Corveus Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Corveus Medical is an early-stage, pre-revenue medical device company focused on the significant unmet need in congestive heart failure (CHF). The company is developing a catheter-based system designed to ablate a specific nerve branch (likely the right greater splanchnic nerve) via a transvenous approach, aiming to halt disease progression in heart failure with preserved ejection fraction (HFpEF) patients. Founded in 2018 and operating from the Texas Medical Center, Corveus is led by a small core team and is in the pre-clinical or early clinical development stage. Its approach is supported by emerging scientific literature on the role of the sympathetic nervous system in HFpEF.

CardiovascularHeart Failure

Technology Platform

Minimally invasive catheter-based system for transvenous ablation of a specific sympathetic nerve branch (likely the right greater splanchnic nerve) to treat heart failure. The platform includes real-time confirmation of nerve deactivation.

Opportunities

The primary opportunity is addressing the massive unmet need in Heart Failure with Preserved Ejection Fraction (HFpEF), a condition affecting millions with no approved disease-modifying drugs.

A successful minimally invasive device could become a standard of care, capturing significant value in a multi-billion dollar global market.

The transvenous approach may offer procedural advantages over surgical or alternative denervation techniques.

Risk Factors

Key risks include the unproven clinical efficacy and durability of the nerve ablation in a large HFpEF patient population, as well as the significant regulatory hurdles for a novel Class III medical device.

The company also faces competition from larger medtech firms exploring neuromodulation for heart failure and the critical challenge of securing adequate insurance reimbursement post-approval.

Competitive Landscape

Corveus operates in the competitive neuromodulation for heart failure space, competing with companies investigating renal denervation (e.g., Medtronic, Recor Medical) and other sympathetic modulation approaches. Its specific targeting of the greater splanchnic nerve is a differentiating focus, but it must compete for clinical adoption, investment, and physician mindshare against more established players with greater resources.

More companies in Neuroscience & CNS →More companies in United States →